{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:46:25Z","timestamp":1791215185021,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T00:00:00Z","timestamp":1506988800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13023-017-0712-3","type":"journal-article","created":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T02:52:31Z","timestamp":1507085551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4035-6592","authenticated-orcid":false,"given":"Joseph","family":"Muenzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tylki-Szyma\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Jego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,3]]},"reference":[{"key":"712_CR1","first-page":"3421","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"EF Neufeld","year":"2001","unstructured":"Neufeld EF, Muenzer J. The Mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, et al., editors. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001. p. 3421\u201352.","edition":"8"},{"key":"712_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249\u201354.","journal-title":"JAMA"},{"key":"712_CR3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s10545-005-0112-z","volume":"28","author":"F Baehner","year":"2005","unstructured":"Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis. 2005;28:1011\u20137.","journal-title":"J Inherit Metab Dis"},{"key":"712_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","volume":"10","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J. Initial report from the Hunter Outcome Survey. Genet Med. 2008;10:508\u201316.","journal-title":"Genet Med"},{"key":"712_CR5","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","volume":"32","author":"SA Jones","year":"2009","unstructured":"Jones SA, Almassy Z, Beck M, Burt K, Clarke JT, Giugliani R, et al. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2009;32:534\u201343.","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl 5","key":"712_CR6","doi-asserted-by":"publisher","first-page":"v49","DOI":"10.1093\/rheumatology\/ker396","volume":"50","author":"V Valayannopoulos","year":"2011","unstructured":"Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50(Suppl 5):v49\u201359.","journal-title":"Rheumatology (Oxford)"},{"key":"712_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","volume":"8","author":"J Muenzer","year":"2006","unstructured":"Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8:465\u201373.","journal-title":"Genet Med"},{"key":"712_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","volume":"13","author":"J Muenzer","year":"2011","unstructured":"Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13:95\u2013101.","journal-title":"Genet Med"},{"key":"712_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/gim.2013.162","volume":"16","author":"R Giugliani","year":"2014","unstructured":"Giugliani R, Hwu WL, Tylki-Szymanska A, Whiteman DA, Pano A. A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy. Genet Med. 2014;16:435\u201341.","journal-title":"Genet Med"},{"issue":"6","key":"712_CR10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10545-017-0075-x","volume":"40","author":"Barbara K. Burton","year":"2017","unstructured":"Burton BK, Jego V, Mikl J, Jones SA. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2017; https:\/\/doi.org\/10.1007\/s10545-017-0075-x . [Epub ahead of print]","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"712_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004;144:581\u20138.","journal-title":"J Pediatr"},{"key":"712_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"P Harmatz","year":"2006","unstructured":"Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148:533\u20139.","journal-title":"J Pediatr"},{"key":"712_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry\u2019s disease. N Engl J Med. 2001;345:9\u201316.","journal-title":"N Engl J Med"},{"key":"712_CR14","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743\u20139.","journal-title":"JAMA"},{"key":"712_CR15","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.4081\/or.2010.e16","volume":"2","author":"B Link","year":"2010","unstructured":"Link B, de Camargo Pinto LL, Giugliani R, Wraith JE, Guffon N, Eich E, et al. Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey. Orthop Rev (Pavia). 2010;2:e16.","journal-title":"Orthop Rev (Pavia)"},{"key":"712_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ymgme.2010.06.011","volume":"101","author":"BK Burton","year":"2010","unstructured":"Burton BK, Guffon N, Roberts J, van der Ploeg AT, Jones SA. Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey. Mol Genet Metab. 2010;101:123\u20139.","journal-title":"Mol Genet Metab"},{"key":"712_CR17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/GIM.0b013e3181f6e74d","volume":"12","author":"NJ Mendelsohn","year":"2010","unstructured":"Mendelsohn NJ, Harmatz P, Bodamer O, Burton BK, Giugliani R, Jones SA, et al. Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey. Genet Med. 2010;12:816\u201322.","journal-title":"Genet Med"},{"key":"712_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/GIM.0b013e318206786f","volume":"13","author":"J Muenzer","year":"2011","unstructured":"Muenzer J, Beck M, Giugliani R, Suzuki Y, Tylki-Szymanska A, Valayannopoulos V, et al. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet Med. 2011;13:102\u20139.","journal-title":"Genet Med"},{"key":"712_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymgme.2011.02.018","volume":"103","author":"BK Burton","year":"2011","unstructured":"Burton BK, Whiteman DA. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2011;103:113\u201320.","journal-title":"Mol Genet Metab"},{"key":"712_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jpeds.2011.01.054","volume":"159","author":"C Kampmann","year":"2011","unstructured":"Kampmann C, Beck M, Morin I, Loehr JP. Prevalence and characterization of cardiac involvement in Hunter syndrome. J Pediatr. 2011;159:327\u201331. e2","journal-title":"J Pediatr"},{"key":"712_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10545-011-9378-5","volume":"35","author":"A Keilmann","year":"2012","unstructured":"Keilmann A, Nakarat T, Bruce IA, Molter D, Malm G. Hearing loss in patients with mucopolysaccharidosis II: data from HOS - the Hunter Outcome Survey. J Inherit Metab Dis. 2012;35:343\u201353.","journal-title":"J Inherit Metab Dis"},{"key":"712_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ymgme.2013.03.001","volume":"109","author":"SA Jones","year":"2013","unstructured":"Jones SA, Parini R, Harmatz P, Giugliani R, Fang J, Mendelsohn NJ. The effect of idursulfase on growth in patients with Hunter syndrome: Data from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2013;109:41\u20138.","journal-title":"Mol Genet Metab"},{"key":"712_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13023-017-0635-z","volume":"12","author":"J Muenzer","year":"2017","unstructured":"Muenzer J, Jones SA, Tylki-Szymanska A, Harmatz P, Mendelsohn NJ, Guffon N, et al. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis. 2017;12:82.","journal-title":"Orphanet J Rare Dis"},{"key":"712_CR24","volume-title":"Diagnostic and statistical manual of mental disorders : DSM-IV-TR","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders : DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Association; 2000.","edition":"4"},{"key":"712_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13023-014-0129-1","volume":"9","author":"R Tomanin","year":"2014","unstructured":"Tomanin R, Zanetti A, D'Avanzo F, Rampazzo A, Gasparotto N, Parini R, et al. Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years. Orphanet J Rare Dis. 2014;9:129.","journal-title":"Orphanet J Rare Dis"},{"key":"712_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ymgmr.2015.03.011","volume":"3","author":"R Parini","year":"2015","unstructured":"Parini R, Rigoldi M, Tedesco L, Boffi L, Brambilla A, Bertoletti S, et al. Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients. Mol Genet Metab Rep. 2015;3:65\u201374.","journal-title":"Mol Genet Metab Rep"},{"key":"712_CR27","first-page":"II19","volume":"9","author":"RB Devereux","year":"1987","unstructured":"Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. Hypertension. 1987;9:II19\u201326.","journal-title":"Hypertension"},{"key":"712_CR28","unstructured":"Wolf DC. Evaluation of the Size, Shape, and Consistency of the Liver. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Boston: Butterworth; 1990."},{"issue":"395\u20139","key":"712_CR29","first-page":"9 e1","volume":"150","author":"R Geiger","year":"2007","unstructured":"Geiger R, Strasak A, Treml B, Gasser K, Kleinsasser A, Fischer V, et al. Six-minute walk test in children and adolescents. J Pediatr. 2007;150(395\u20139):9 e1\u20132.","journal-title":"J Pediatr"},{"key":"712_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","volume":"90","author":"J Muenzer","year":"2007","unstructured":"Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A. A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007;90:329\u201337.","journal-title":"Mol Genet Metab"},{"key":"712_CR31","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1111\/j.1651-2227.2011.02385.x","volume":"101","author":"A Tylki-Szymanska","year":"2012","unstructured":"Tylki-Szymanska A, Jurecka A, Zuber Z, Rozdzynska A, Marucha J, Czartoryska B. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up. Acta Paediatr. 2012;101:e42\u20137.","journal-title":"Acta Paediatr"},{"key":"712_CR32","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.medcli.2015.06.015","volume":"145","author":"J Dalmau Serra","year":"2015","unstructured":"Dalmau Serra J, Vitoria Minana I, Calderon Fernandez R, Cortell AI. Clinical response to long term enzyme replacement treatment in children, adolescent and adult patients with Hunter syndrome. Med Clin (Barc). 2015;145:392\u20138.","journal-title":"Med Clin (Barc)"},{"key":"712_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13023-015-0259-0","volume":"10","author":"N Guffon","year":"2015","unstructured":"Guffon N, Heron B, Chabrol B, Feillet F, Montauban V, Valayannopoulos V. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study. Orphanet J Rare Dis. 2015;10:43.","journal-title":"Orphanet J Rare Dis"},{"key":"712_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","volume":"99","author":"T Okuyama","year":"2010","unstructured":"Okuyama T, Tanaka A, Suzuki Y, Ida H, Tanaka T, Cox GF, et al. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol Genet Metab. 2010;99:18\u201325.","journal-title":"Mol Genet Metab"},{"key":"712_CR35","doi-asserted-by":"crossref","unstructured":"Gibson GJ. Clinical Tests of Respiratory Function 3rd Edition ed. Boca Raton: CRC Press; 2008.","DOI":"10.1201\/b13346"},{"key":"712_CR36","first-page":"599","volume":"13","author":"R Giugliani","year":"1990","unstructured":"Giugliani R, Dutra-Filho C, Barth M, Enk V, Netto C. Age-related concetrations of glycosaminoglycans in random urine: a contribution to the laboratorial detection of mucopolysaccharidoses. Rev Brasil Genet. 1990;13:599\u2013605.","journal-title":"Rev Brasil Genet"},{"key":"712_CR37","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s10545-011-9359-8","volume":"34","author":"EA Braunlin","year":"2011","unstructured":"Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP, et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011;34:1183\u201397.","journal-title":"J Inherit Metab Dis"},{"key":"712_CR38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s12098-013-1288-0","volume":"81","author":"P Amatya","year":"2014","unstructured":"Amatya P, Shah D, Gupta N, Bhatta NK. Clinical and ultrasonographic measurement of liver size in normal children. Indian J Pediatr. 2014;81:441\u20135.","journal-title":"Indian J Pediatr"},{"key":"712_CR39","doi-asserted-by":"publisher","first-page":"e1228","DOI":"10.1542\/peds.2008-0999","volume":"124","author":"J Muenzer","year":"2009","unstructured":"Muenzer J, Beck M, Eng CM, Escolar ML, Giugliani R, Guffon NH, et al. Multidisciplinary management of Hunter syndrome. Pediatrics. 2009;124:e1228\u201339.","journal-title":"Pediatrics"},{"key":"712_CR40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ymgme.2013.08.002","volume":"110","author":"AJ Barbier","year":"2013","unstructured":"Barbier AJ, Bielefeld B, Whiteman DA, Natarajan M, Pano A, Amato DA. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase. Mol Genet Metab. 2013;110:303\u201310.","journal-title":"Mol Genet Metab"},{"key":"712_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","volume":"111","author":"J Muenzer","year":"2014","unstructured":"Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab. 2014;111:63\u201372.","journal-title":"Mol Genet Metab"},{"key":"712_CR42","first-page":"79","volume":"5","author":"S Sestito","year":"2015","unstructured":"Sestito S, Ceravolo F, Grisolia M, Pascale E, Pensabene L, Concolino D. Profile of idursulfase for the treatment of Hunter syndrome. Res Rep Endocr Disord. 2015;5:79\u201390.","journal-title":"Res Rep Endocr Disord"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-017-0712-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-017-0712-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-017-0712-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T18:29:09Z","timestamp":1659551349000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-017-0712-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,3]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["712"],"URL":"https:\/\/doi.org\/10.1186\/s13023-017-0712-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,3]]},"assertion":[{"value":"24 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional Review Board\/Ethics Committee approval was obtained for all participating centres. HOS is conducted in accordance with Good Pharmacoepidemiology Practices, Good Research for Comparative Effectiveness principles and the relevant principles of the International Conference on Harmonisation (ICH) Good Clinical Practice guidelines (ICH E6). Each patient, their parents or a legal representative provided signed and dated written informed consent for participation in HOS.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Each patient, their parents or a legal representative provided informed consent for publication of data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JM is a consultant to BioMarin, Eloxx, Sanofi Genzyme, Green Cross, Janssen Pharmaceuticals, PTC Therapeutics and Shire. He also serves on advisory boards for BioMarin, Sanofi Genzyme and Shire. He is principal investigator for phase 1\/2 and phase 2\/3 trials, sponsored by Shire, that investigate intrathecal ERT for patients with the severe form of Hunter syndrome.RG has received travel grants from BioMarin, Sanofi Genzyme and Shire, research grants from Actelion Pharmaceuticals, Alexion, Amicus, BioMarin, Sanofi Genzyme and Shire, and honoraria for speaking engagements from Actelion Pharmaceuticals, Alexion, Amicus, BioMarin, Sanofi Genzyme, PTC Therapeutics and Shire.MS has received grants, travel support and honoraria from Actelion Pharmaceuticals, Alexion, BioMarin, Sanofi Genzyme, Shire and PTC Therapeutics.AT-S has received travel grants and speaker fees from BioMarin, Sanofi Genzyme, Shire and Synageva BioPharma.Ms. Jego is an employee of Cytel, Inc. and has received consulting fees from Shire.MB has received honoraria, travel support and unrestricted grants from Actelion Pharmaceuticals, BioMarin, Sanofi Genzyme and Shire.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"161"}}